Spinocerebellar Degeneration
9
1
1
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
78%
7 trials in Phase 3/4
0%
0 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (9)
Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration
C-Trelin Orally Disintegrated(OD) Tablet 5mg in Ataxia Due to Spinocerebellar Degeneration
An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)